Wuhan Keqian Biology Co.,Ltd (SHA:688526)
China · Delayed Price · Currency is CNY 11.74
+0.04 (0.34%)
Nov 6, 2026, 11:28 AM CST
SHA:688526 Ratios and Metrics
Market cap in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Total Valuation
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Nov '26 Nov 5, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
| 5,446 | 7,079 | 6,636 | 9,501 | 10,443 | 12,805 | |
Market Cap Growth | -26.44% | 6.68% | -30.15% | -9.03% | -18.45% | -33.80% |
Enterprise Value | 3,685 | 5,366 | 5,635 | 8,216 | 9,522 | 10,651 |
Last Close Price | 11.70 | 14.57 | 13.28 | 18.52 | 20.19 | 24.60 |
Price Ratios
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Nov '26 Nov 5, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
PE Ratio | 24.14 | 16.91 | 17.36 | 24.00 | 25.50 | 22.44 |
Forward PE | 11.14 | 14.51 | 13.51 | 14.86 | 16.95 | 17.49 |
PS Ratio | 6.90 | 7.45 | 7.05 | 8.93 | 10.43 | 11.61 |
PB Ratio | 1.33 | 1.67 | 1.68 | 2.48 | 2.99 | 4.06 |
P/TBV Ratio | 1.35 | 1.70 | 1.71 | 2.52 | 3.04 | 4.14 |
P/FCF Ratio | 21.56 | 20.54 | 23.22 | 21.91 | 32.55 | 81.65 |
P/OCF Ratio | 14.33 | 15.11 | 16.90 | 17.66 | 24.65 | 24.10 |
EV Ratios
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Nov '26 Nov 5, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
EV/Sales Ratio | 4.66 | 5.65 | 5.98 | 7.72 | 9.51 | 9.66 |
EV/EBITDA Ratio | 12.40 | 11.11 | 13.32 | 17.46 | 19.83 | 16.68 |
EV/EBIT Ratio | 20.73 | 14.45 | 17.89 | 22.99 | 24.85 | 18.50 |
EV/FCF Ratio | 14.56 | 15.57 | 19.72 | 18.95 | 29.68 | 67.92 |
Financial Efficiency
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Nov '26 Nov 5, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Debt / Equity Ratio | 0.00 | 0.00 | 0.00 | 0.08 | 0.08 | 0.03 |
Debt / EBITDA Ratio | 0.02 | 0.01 | 0.02 | 0.62 | 0.58 | 0.12 |
Debt / FCF Ratio | 0.03 | 0.02 | 0.02 | 0.68 | 0.87 | 0.50 |
Net Debt / Equity Ratio | -0.43 | -0.56 | -0.49 | -0.39 | -0.47 | -0.39 |
Net Debt / EBITDA Ratio | -6.04 | -4.92 | -4.55 | -3.15 | -3.46 | -1.94 |
Net Debt / FCF Ratio | -6.99 | -6.90 | -6.74 | -3.42 | -5.18 | -7.89 |
Asset Turnover | 0.17 | 0.21 | 0.21 | 0.24 | 0.25 | 0.32 |
Inventory Turnover | 2.44 | 2.45 | 2.67 | 2.05 | 2.01 | 2.56 |
Quick Ratio | 5.10 | 5.88 | 4.95 | 2.85 | 3.82 | 3.34 |
Current Ratio | 7.80 | 6.40 | 5.34 | 3.38 | 4.11 | 3.58 |
Return on Equity (ROE) | 5.45% | 10.19% | 9.81% | 10.78% | 12.30% | 19.47% |
Return on Assets (ROA) | 2.37% | 5.00% | 4.29% | 4.93% | 5.90% | 10.53% |
Return on Invested Capital (ROIC) | 8.28% | 16.57% | 12.55% | 14.74% | 17.90% | 39.80% |
Return on Capital Employed (ROCE) | 4.20% | 8.60% | 7.80% | 9.10% | 10.20% | 17.80% |
Yields
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Nov '26 Nov 5, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Earnings Yield | 4.14% | 5.92% | 5.76% | 4.17% | 3.92% | 4.46% |
FCF Yield | 4.64% | 4.87% | 4.31% | 4.56% | 3.07% | 1.23% |
Dividend Yield | 5.45% | 4.10% | 3.01% | 2.11% | 0.85% | 0.69% |
Payout Ratio | 131.50% | 47.64% | 53.51% | 24.52% | 22.83% | 23.97% |
Buyback Yield / Dilution | 0.51% | 0.22% | -0.10% | -0.10% | -0.29% | -20.20% |
Total Shareholder Return | 5.98% | 4.32% | 2.90% | 2.02% | 0.56% | -19.51% |